UNCY logo

Unicycive Therapeutics, Inc. Common Stock


UNCY: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.


Show UNCY Financials

Consumer Interest
SEC Filings

Recent trades of UNCY by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by UNCY's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use Aug. 09, 2022
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of UNCY in WallStreetBets Daily Discussion


Recent insights relating to UNCY

CNBC Recommendations

Recent picks made for UNCY stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in UNCY

Corporate Flights

Flights by private jets registered to UNCY